Reference List

  1. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17‑26.
  2. Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol. 2004;70:10‑12.
  3. Souness JE, Griffin M, Maslen C, et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low‑affinity' phosphodiesterase 4 conformer. Br J Pharmacol. 1996;118:649‑658.
  4. Ma R, Yang BY, Wu CY. A selective phosphodiesterase 4 (PDE4) inhibitor Zl‑n‑91 suppresses IL‑17 production by human memory Th17 cells. Int Immunopharmacol. 2008;8:1408‑1417.
  5. Essayan DM, Huang SK, Kagey‑Sobotka A, Lichtenstein LM. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen‑induced cytokine gene expression in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol. 1995;13:692‑702.
  6. Oger S, Mehats C, Dallot E, Cabrol D, Leroy MJ. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide‑stimulated prostaglandin E2 production and matrix metalloproteinase‑9 activity in human amniochorionic membranes. J Immunol. 2005;174:8082‑8089.
  7. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64 Suppl 2:ii87‑ii90.
  8. Wollina U, Unger L, Heinig B, Kittner T. Psoriatic arthritis. Dermatol Ther. 2010;23:123‑136.
  9. Van Parijs L, Abbas AK. Homeostasis and self‑tolerance in the immune system: turning lymphocytes off. Science. 1998;280:243‑248.
  10. Taskén K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84:137‑167.
  11. Jimenez JL, Punzon C, Navarro J, Munoz‑Fernandez MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor‑kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther. 2001;299:753‑759.
  12. Liu J, Chen M, Wang X. Calcitonin gene‑related peptide inhibits lipopolysaccharide‑induced interleukin‑12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology. 2000;101:61‑67.
  13. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 induces IL‑23 production in bone marrow‑derived dendritic cells. FASEB J. 2004;18:1318‑1320.
  14. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti‑inflammatory and pro‑inflammatory roles of TGF‑beta, IL‑10, and IL‑22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009;9:447‑453.
  15. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti‑inflammatory activities of cAMP‑elevating agents: enhancement of IL‑10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63:101‑107.
  16. Intracellular signal transduction. In: Purves D, Augustine GL, Fitzpatrick D et al., eds. Neuroscience, Sunderland, MA: Sinauer Associates; 2001.
  17. Qi XF, Kim DH, Yoon YS, et al. The adenylyl cyclase‑cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF‑kappaB in HaCaT keratinocytes. Mol Immunol. 2009;46:1925‑1934.
  18. Grandjean‑Laquerriere A, Le NR, Gangloff SC, Guenounou M. Differential regulation of TNF‑alpha, IL‑6 and IL‑10 in UVB‑irradiated human keratinocytes via cyclic AMP/protein kinase A pathway. Cytokine. 2003;23:138‑149.
  19. Hertz AL, Bender AT, Smith KC, et al. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte‑derived macrophages. Proc Natl Acad Sci U S A. 2009;106:21978‑21983.
  20. Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1‑polarizing capacity. Int Immunol. 2003;15:827‑835.
  21. Wall EA, Zavzavadjian JR, Chang MS, et al. Suppression of LPS‑induced TNF‑alpha production in macrophages by cAMP is mediated by PKA‑AKAP95‑p105. Sci Signal. 2009;2:ra28.
  22. Avni D, Philosoph A, Meijler MM, Zor T. The ceramide‑1‑phosphate analogue PCERA‑1 modulates tumour necrosis factor‑alpha and interleukin‑10 production in macrophages via the cAMP‑PKA‑CREB pathway in a GTP‑dependent manner. Immunology. 2010;129:375‑385.
  23. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF‑kappa B pathway downstream of immunoreceptors. Eur J Immunol. 2005;35:31‑41.
  24. Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor‑alpha production and inhibition of cAMP phosphodiesterase activity. Immunology. 1993;78:520‑525.
  25. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin‑E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. 1995;181:775‑779.
  26. Serezani CH, Ballinger MN, Aronoff DM, Peters‑Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39:127‑132.
  27. Luo M, Jones SM, Phare SM, Coffey MJ, Peters‑Golden M, Brock TG. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5‑lipoxygenase on serine 523. J Biol Chem. 2004;279:41512‑41520.
  28. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross‑talk, desensitization and compartmentalization. Biochem J. 2003;370:1‑18.
  29. Mosenden R, Tasken K. Cyclic AMP‑mediated immune regulation‑‑overview of mechanisms of action in T cells. Cell Signal. 2011;23:1009‑1016.
  30. Immune system: T cells. National Institute of Allergy and Infectious Diseases [serial online] 2008; Accessed April 10, 2012.
  31. Johnson‑Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine‑producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol. 2009;29:247‑256.
  32. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 2003;17:1831‑1841.
  33. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide‑induced tumor necrosis factor‑alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol. 1995;48:747‑757.
  34. Chujor CS, Hammerschmid F, Lam C. Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines. J Invest Dermatol. 1998;110:287‑291.
  35. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes‑‑functional importance of phosphodiesterase 4. Br J Pharmacol. 2002;135:609‑618.
  36. Carlson CR, Lygren B, Berge T, et al. Delineation of type I protein kinase A‑selective signaling events using an RI anchoring disruptor. J Biol Chem. 2006;281:21535‑21545.
  37. Phosphodiesterases As Drug Targets. Francis SH, Houslay MD, Conti M, eds. Phosphodiesterases As Drug Targets. Berlin‑Heidelberg, Germany: Springer‑Verlag, 2011. Handbook of Experimental Pharmacology.
  38. Essayan DM, Huang SK, Kagey‑Sobotka A, Lichtenstein LM. Differential efficacy of lymphocyte‑ and monocyte‑selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen‑driven proliferation and cytokine gene expression. J Allergy Clin Immunol. 1997;99:28‑37.
  39. Layseca‑Espinoza E, Sánchez‑Madrid F, González‑Amaro R. Phosphodiesterase inhibitors as immunomodulatory drugs. Immunología. 2003;22:39‑52.
  40. Boniface K, Guignouard E, Pedretti N, et al. A role for T cell‑derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol. 2007;150:407‑415.
  41. van Kuijk AW, Reinders‑Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551‑1557.
  42. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion‑free psoriatic skin is characterized by a T‑helper type 1 cell‑mediated response. J Invest Dermatol. 1993;101:701‑705.
  43. Spadaro A, Rinaldi T, Riccieri V, Valesini G, Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis. 2002;61:174‑176.
  44. Ritchlin C, Haas‑Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544‑1552.
  45. Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor‑alpha blockade in the knee joint. Arthritis Res Ther. 2010;12:R148.
  46. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL‑17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419‑429.
  47. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL‑12p70 and IL‑23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci. 2009;54:99‑105.
  48. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient‑reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol. 2011;30:877‑885.
  49. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first‑degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000;123 ( Pt 6):1102‑1111.
  50. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case‑control study. J Am Acad Dermatol. 2007;56:629‑634.
  51. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194‑2201.
  52. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075‑1082.
  53. Wu Y, Mills D, Bala M. Impact of psoriasis on patients' work and productivity: a retrospective, matched case‑control analysis. Am J Clin Dermatol. 2009;10:407‑410.
  54. Mease PJ. Psoriatic arthritis ‑ update on pathophysiology, assessment, and management. Bull NYU Hosp Jt Dis. 2010;68:191‑198.
  55. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today. 1993;14:75‑78.
  56. Piskin G, Sylva‑Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL‑23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908‑1915.
  57. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851‑864.
  58. König A, Krenn V, Gillitzer R, et al. Inflammatory infiltrate and interleukin‑8 expression in the synovium of psoriatic arthritis‑‑an immunohistochemical and mRNA analysis. Rheumatol Int. 1997;17:159‑168.
  59. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF‑alpha and inducible nitric oxide synthase‑expressing dendritic cells in psoriasis and reduction with efalizumab (anti‑CD11a). Proc Natl Acad Sci U S A. 2005;102:19057‑19062.
  60. Okubo Y, Koga M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci. 1998;17:223‑232.
  61. Fuentes‑Duculan J, Suarez‑Farinas M, Zaba LC, et al. A subpopulation of CD163‑positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130:2412‑2422.
  62. Aronson PJ. A review of the role of neutrophils in psoriasis and related disorders. Dermatology Online Journal [serial online] 2008;14.
  63. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon‑gamma, interleukin‑2, and tumor necrosis factor‑alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752‑759.
  64. Zarrabeitia MT, Farinas MC, Rodriguez‑Valverde V, Riancho JA, Llaca HF. T and B cell function in psoriasis and psoriatic arthropathy. Allergol Immunopathol (Madr ). 1989;17:155‑159.
  65. Röhner E, Matziolis G, Perka C, et al. Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases. Immunol Res. 2012;52(3):169-175.
  66. Gröne A. Keratinocytes and cytokines. Vet Immunol Immunopathol. 2002;88:1‑12.
  67. Cumberbatch M, Dearman RJ, Kimber I. Interleukin 1 beta and the stimulation of Langerhans cell migration: comparisons with tumour necrosis factor alpha. Arch Dermatol Res. 1997;289:277‑284.
  68. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496‑509.
  69. Cooper GM. The Cell: A Molecular Approach, ed 2. Sunderland, MA: Sinauer Associates; 2000.
  70. Luo JL, Kamata H, Karin M. IKK/NF‑κB signaling: balancing life and death ‑ a new approach to cancer therapy. J Clin Invest. 2005;115(10):2625‑2632.
  71. Jacinto E, Werlen G, Karin M. Cooperation between Syk and Rac1 leads to synergistic JNK activation in T lymphocytes. Immunity. 1998:8(31):31‑41.
  72. Chen BC, Lin WW. PKC‑ and ERK‑dependent activation of IkB kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor‑mediated CaMK activation. Br J Pharmacol. 2001:134‑1055‑1065.
  73. Swedish Royal Academy of Sciences. Scientific Background on the Nobel Prize in Chemistry 2012: Studies of G‑protein–coupled receptors. Nobel Foundation. 2012.
  74. Oliveira RF, Terrin A, Di Benedetto G, Cannon RC, Koh W, et al. The role of type 4 phosphodiesterases in generating microdomains of cAMP: large scale stochastic simulations. PLoS ONE. 2010;5(7):e11725.
  75. Parry GC, Mackman N. Role of cyclic AMP response element‑binding protein in cyclic AMP inhibition of NF‑κB‑mediated transcription. J Immunol. 1997;159(11):5450‑5456.
  76. Skålhegg BS, Taskén K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci. 2000;5:D678‑D693.
  77. Brenner S, Prösch S, Schenke‑Layland K, et al. cAMP‑induced interleukin‑10 promoter activation depends on CCAAT/enhancer‑binding protein expression and monocytic differentiation. J Biol Chem. 2003;278(8):5597‑5604.
  78. Furst D, Smith SL. What are TNF‑alpha inhibitors? What should patients know? American Autoimmune Related Diseases Association Web site. Accessed June 17, 2013
  79. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. May 2008;58(5):826-850.
  80. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. The Journal of rheumatology. Aug 2013;40(8):1349-1356.
  81. Data on file. Celgene Corp.
  82. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnairesss. Ann Rheum Dis. 2013;72:736-740.
  83. Zarco P, López-Estebaránz JL, Fernandez-Sueiro JL, García-Calvo C. Prevalence of psoriatic arthritis in psoriatic patients attending dermatologists’ units in Spain: PREVAL study. Presented at the 3rd World Psoriasis and Psoriatic Arthritis Conference; June 27-July 1, 2012; Stockholm, Sweden.
  84. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174
  85. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med. Jul 2013;19(7):822-824.
  86. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028.
  87. National Psoriasis Foundation. An Overview of Psoriasis and Psoriatic Arthritis. Portland, OR: National Psoriasis Foundation; 2009.
  88. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
  89. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899-1912.
  90. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385-422.
  91. Balato A, Balato N, Megna M, Schiatarella M, Lembo S, Ayala F. Pathogenesis of psoriasis: the role of pro-inflammatory cytokines produced by keratinocytes. In: Soung J, Koo B, eds. Psoriasis. Rijeka, Croatia: InTech Europe; 2012.
  92. Dogan S, Atakan N. Psoriasis: a disease of systemic inflammation with comorbidities. In: Lima H, ed. Psoriasis—Types, Causes and Medication. Rijeka, Croatia: InTech Europe; 2013.
  93. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-1356.
  94. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.
  95. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2013. doi: 10.1016/j.jaad.2013.12.018.
  96. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64 Suppl 2:ii26-29.
  97. Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51(2):275-283.
  98. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680-689.
  99. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol. 2009;36(5):1012-1020.

See PDE4’s Role in Autoimmune Disease

See PDE4's Role in Autoimmune Disease
Watch full story now »